Viet-Thi Tran1,2, Carolina Riveros1,2, Bérangère Clepier3, Moïse Desvarieux1,4, Camille Collet3, Youri Yordanov5,6, Philippe Ravaud1,2,4. 1. Université de Paris, CRESS, INSERM, INRA, Paris, France. 2. Centre d'Epidémiologie Clinique, Hôpital Hôtel-Dieu, AP-HP, Paris, France. 3. Assistance Publique Hôpitaux de Paris, Paris, France. 4. Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York, USA. 5. Service d'Accueil des Urgences, Hôpital Saint Antoine, AP-HP, Sorbonne Université, Paris,France. 6. INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR-S, Paris, France.
Abstract
BACKGROUND: To develop and validate patient-reported instruments, based on patients' lived experiences, for monitoring the symptoms and impact of long coronavirus disease (covid). METHODS: The long covid Symptom and Impact Tools (ST and IT) were constructed from the answers to a survey with open-ended questions to 492 patients with long COVID. Validation of the tools involved adult patients with suspected or confirmed coronavirus disease 2019 (COVID-19) and symptoms extending over 3 weeks after onset. Construct validity was assessed by examining the relations of the ST and IT scores with health-related quality of life (EQ-5D-5L), function (PCFS, post-COVID functional scale), and perceived health (MYMOP2, Measure yourself medical outcome profile 2). Reliability was determined by a test-retest. The "patient acceptable symptomatic state" (PASS) was determined by the percentile method. RESULTS: Validation involved 1022 participants (55% with confirmed COVID-19, 79% female, and 12.5% hospitalized for COVID-19). The long COVID ST and IT scores were strongly correlated with the EQ-5D-5L (rs = -0.45 and rs = -0.59, respectively), the PCFS (rs = -0.39 and rs = -0.55), and the MYMOP2 (rs = -0.40 and rs = -0.59). Reproducibility was excellent with an interclass correlation coefficient of 0.83 (95% confidence interval .80 to .86) for the ST score and 0.84 (.80 to .87) for the IT score. In total, 793 (77.5%) patients reported an unacceptable symptomatic state, thereby setting the PASS for the long covid IT score at 30 (28 to 33). CONCLUSIONS: The long covid ST and IT tools, constructed from patients' lived experiences, provide the first validated and reliable instruments for monitoring the symptoms and impact of long covid.
BACKGROUND: To develop and validate patient-reported instruments, based on patients' lived experiences, for monitoring the symptoms and impact of long coronavirus disease (covid). METHODS: The long covid Symptom and Impact Tools (ST and IT) were constructed from the answers to a survey with open-ended questions to 492 patients with long COVID. Validation of the tools involved adult patients with suspected or confirmed coronavirus disease 2019 (COVID-19) and symptoms extending over 3 weeks after onset. Construct validity was assessed by examining the relations of the ST and IT scores with health-related quality of life (EQ-5D-5L), function (PCFS, post-COVID functional scale), and perceived health (MYMOP2, Measure yourself medical outcome profile 2). Reliability was determined by a test-retest. The "patient acceptable symptomatic state" (PASS) was determined by the percentile method. RESULTS: Validation involved 1022 participants (55% with confirmed COVID-19, 79% female, and 12.5% hospitalized for COVID-19). The long COVID ST and IT scores were strongly correlated with the EQ-5D-5L (rs = -0.45 and rs = -0.59, respectively), the PCFS (rs = -0.39 and rs = -0.55), and the MYMOP2 (rs = -0.40 and rs = -0.59). Reproducibility was excellent with an interclass correlation coefficient of 0.83 (95% confidence interval .80 to .86) for the ST score and 0.84 (.80 to .87) for the IT score. In total, 793 (77.5%) patients reported an unacceptable symptomatic state, thereby setting the PASS for the long covid IT score at 30 (28 to 33). CONCLUSIONS: The long covid ST and IT tools, constructed from patients' lived experiences, provide the first validated and reliable instruments for monitoring the symptoms and impact of long covid.
Authors: Beatriz Carpallo-Porcar; Laura Romo-Calvo; Sara Pérez-Palomares; Carolina Jiménez-Sánchez; Pablo Herrero; Natalia Brandín-de la Cruz; Sandra Calvo Journal: PLoS One Date: 2022-07-19 Impact factor: 3.752
Authors: César Fernández-de-Las-Peñas; José D Martín-Guerrero; Lidiane L Florencio; Esperanza Navarro-Pardo; Jorge Rodríguez-Jiménez; Juan Torres-Macho; Oscar J Pellicer-Valero Journal: Infection Date: 2022-04-22 Impact factor: 7.455
Authors: Florent Besnier; Béatrice Bérubé; Jacques Malo; Christine Gagnon; Catherine-Alexandra Grégoire; Martin Juneau; François Simard; Philippe L'Allier; Anil Nigam; Josep Iglésies-Grau; Thomas Vincent; Deborah Talamonti; Emma Gabrielle Dupuy; Hânieh Mohammadi; Mathieu Gayda; Louis Bherer Journal: Int J Environ Res Public Health Date: 2022-03-31 Impact factor: 3.390